solvents

Nevada: DigiPath Labs Completes First Medical Marijuana Test

DigiPathScientistInLab

DigiPath Labs of Las Vegas, the cannabis testing subsidiary of DigiPath, Inc., on Thursday announced that it has successfully completed its first commercial test of cannabis material.

In the short time it's been open, the company said it has already proven that it has the equipment and knowledge needed to reliably test medical cannabis for safety and potency.

"We are open for business," said Todd Denkin, president of DigiPath Labs. "It's been a very long and arduous process, but we jumped through all the hoops and cleared all the obstacles, and now we're testing cannabis products and generating revenue, an important milestone to our shareholders."

As one of only two labs currently operating in Southern Nevada, DigiPath Labs is positioned at the forefront of what is anticipated to become a rapidly growing industry in the Silver State. According to ArcView, the legal cannabis market exploded from $1.5 billion in 2013 to $2.7 billion in 2014—a 74 percent increase in just one year.

Greenwave Advisors estimates that the market could reach $35 billion by 2020 if marijuana is fully legalized across the country, or $21 billion under the more likely scenario of 12 states legalizing recreational use and 37 states legalizing medical use.

Nevada: DigiPath Inks Deal With First Medical Marijuana Dispensary In Vegas

DigiPathInc(molecular-logo)

DigiPath Labs of Las Vegas, a subsidiary of DigiPath, Inc., on Thursday announced it has entered into a one-year agreement with Euphoria Wellness to conduct comprehensive safety and potency tests on the products Euphoria will sell in its Las Vegas medical marijuana dispensary.

Euphoria Wellness, expected to be the first cannabis dispensary to open in Las Vegas, said it chose to partner with DigiPath Labs as part of its strategy to set the highest medical marijuana patient safety and education standards in the industry.

"DigiPath Labs will analyze samples of products sold by Euphoria Wellness for unsafe levels of contaminants such as heavy metals, microbes, mycotoxins, pesticides, and solvents, which can exacerbate patient health issues," says Todd Denkin, president of DigiPath Labs. "We will also quantify cannabinoid and terpenoid levels and deliver detailed reports that Euphoria's staff can use to help patients."

Comprehensive cannabis potency testing is critical for patient care, according to DigiPath. Cannabis is believed to contain over 400 medicinal compounds, most notably cannabinoids and terpenoids, each of which affects the body differently.

One compound, THC, is known to induce cancerous cell death. Another compound, CBD, keeps certain cancers from spreading. Different compounds can reduce tissue inflammation, treat epilepsy, and fight methicillin-resistant staphylococcus aureus (MRSA) infections.

Nevada: DigiPath Gets State Approval For Cannabis Testing Lab In Las Vegas

DigiPathScientistInLab

DigiPath, Inc., an independent cannabis testing and media firm, on Thursday announced that it has received approval from the state of Nevada for its DigiPath Labs subsidiary to open and operate a cannabis testing laboratory at 6450 Cameron Street, Suite 113, in Las Vegas.

DigiPath Labs is in the process of applying for construction permits, ordering equipment, and hiring staff in anticipation of opening the Cameron Street laboratory. To expedite construction, the company is working with a local architectural firm it engaged during the application process. The lab is expected to open its doors to customers in early 2015.

"We are grateful to the State of Nevada for helping to advance our goal of setting a new benchmark for medical cannabis testing and safety screening," said Todd Denkin, CEO of DigiPath, Inc.

"DigiPath Labs is dedicated to increasing transparency of the ingredients inside cannabis-based products," Denkin said. "We believe that this information will benefit patients and dispensaries by providing them with important information regarding the products being sold for consumption."

DigiPath Labs will screen medicinal cannabis for potentially harmful contaminants, including:

• Solvents
• Pesticides
• Mold
• Heavy metals, including mercury, arsenic, lead, and cadmium
• Biological toxins, such as aflatoxin, ricin, and botulinum toxins
• Residual organic chemicals used in extraction
• Microbial contaminants including E. coli, salmonella, and Aspergillus

Syndicate content